Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...